OMF is fundraising to support open, collaborative research to find effective treatments and diagnostic markers for ME/CFS, Long COVID, and related diseases.
OMF’s large-scale biomarker project, BioQuest, is working to incorporate subtype identification into its study. Read more about the project on our website: https://t.co/ebR339ufm0.
#MECFS
🧬Science Wednesdays: Subtyping
Subtyping is the act of identifying smaller groups within a larger group of people. In the context of disease, subtypes are typically variations of the larger disease (e.g., HER2+ breast cancer is a subtype of breast cancer).
As ME/CFS is a heterogeneous disease, it’s likely that there are subtypes of the disease to identify. Subtyping might be particularly important for helping guide treatments.
As May Momentum comes to a close, we want to leave you with a taste of why our researchers do what they do.
Watch the full conversation here: https://t.co/xbdDV0w7Jt
Today at the Invest in ME Conference, Dr. Maureen Hanson — member of OMF's Scientific Advisory Board — presented "Searching for Chronic Infection in ME."
Thank you, Dr. Hanson, for the research that moves us closer to answers for the millions living with ME/CFS.
🧬Science Wednesdays: Autonomic nervous system
The autonomic nervous system controls involuntary actions in the body like heart rate, blood pressure, digestion, and more.
OMF’s clinical trial, the Life Improvement Trial (LIFT), is investigating two drugs:pyridostigmine and low-dose naltrexone. Pyridostigmine has been used off-label to manage dysautonomia, so the LIFT may, in part, help to address dysautonomia in ME/CFS.
We are excited to be going to the Invest In ME conference outside of Cambridge England again this year. Ron Davis and Rob Phair, are both going to be speakers. I will be doing my usual schmoozing around with all the researchers!
OMF’s Melbourne ME/CFS Collaboration has made strides toward developing a diagnostic algorithm for ME/CFS. Read more about it, including the sensitivity and specificity of the algorithm in the paper: https://t.co/N2cU3O4IAL.
🧬Science Wednesdays: Sensitivity vs specificity
Sensitivity and specificity are terms that describe how good something is at correctly identifying a condition (e.g., people within a population that have a disease).
In ME/CFS research, sensitivity and specificity particularly come into play when trying to develop a diagnostic tool. Currently, there is no objective way to diagnose ME/CFS, so a diagnostic tool that is both sensitive and specific is crucial.
Linda Tannenbaum, Founder and CEO of OMF, will deliver the inaugural lecture of Faculty of Medicine of the University of Lisbon’s new Open Lectures series on May 25.
One day left to take the CTN Lite survey.
We know energy is precious. If you have a few minutes to share your perspective, it goes straight to the researchers working on what comes next.
Closes tomorrow: https://t.co/MVgAcHzxhT
Open Medicine Foundation aims to break the traditional mould and remove research silos via our Collaborative Approach to Systems Research model, bringing together different areas of expertise to create a more holistic approach.
🧬 Science Wednesdays: Multi-system chronic complex disease
What is a multi-system chronic complex disease?
While the term multi-system chronic complex disease is perhaps overwhelming at first, each component is relatively straightforward when you break it down.
Impact on Approaching Research Traditionally, medical care systems and research institutes are set up to study, understand, and treat diseases via specific, singular systems. This approach is not sufficient for addressing a multi-system chronic complex disease, however.